天 辰 生 物

LongBio Pharma (Suzhou) Co., Ltd.
天辰生物醫藥(蘇州)股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 1779)

PROPOSED CHANGE OF NON-EXECUTIVE DIRECTOR AND INSIDE INFORMATION PROPOSED IMPLEMENTATION OF THE H SHARE FULL CIRCULATION

PROPOSED CHANGE OF NON-EXECUTIVE DIRECTOR

Proposed Resignation of Non-executive Director

The board (the "**Board**") of directors (the "**Directors**") of LongBio Pharma (Suzhou) Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") hereby announces that Dr. Chen Kan (陳侃) ("**Dr. Chen**") proposed to resign as a non-executive Director with effect from August 31, 2026 in order to devote more time to other business commitments.

Dr. Chen has confirmed that he has no disagreement with the Board and there are no matters relating to his resignation that need to be brought to the attention of the shareholders of the Company (the "**Shareholders**") or The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

The Board would like to express its sincere gratitude to Dr. Chen for his valuable contributions to the Company during his term of office.

Proposed Appointment of Non-executive Director

The Board also announces that, having considered the recommendation of the nomination committee of the Board, the Board has resolved to propose the appointment of Mr. Xue Kailu (薛凱路) ("**Mr. Xue**") as a non-executive Director. The proposed appointment of Mr. Xue is subject to approval by the Shareholders by way of ordinary resolution at an extraordinary general meeting of the Company (the "**EGM**") to be convened. The term of office of Mr. Xue shall commence from the date of approval at the EGM and expire upon the conclusion of the term of the current session of the Board.

The biographical details of Mr. Xue are set out below:

Mr. Xue Kailu (薛凱路), aged 39, has over 17 years of experience in biological analysis. From June 2009 to October 2016, Mr. Xue worked as a project manager of WXAT Shanghai (上海藥明康德新藥開發有限公司) and WuXi AppTec (Wuhan) Co., Ltd. (武漢藥明康德新藥開發有限公司), both of which are subsidiaries of WuXi AppTec Co., Ltd. (無錫藥明康德新藥開發股份有限公司), a company listed on the Stock Exchange (stock code: 2359) and Shanghai Stock Exchange (stock code: 603259). From November 2016 to April 2017, he worked at Caresun Pharmaceutical Co., Ltd. (康誠科瑞醫藥研發(武漢)有限公司) ("**Caresun Pharmaceutical**") as the director of analytics. From May 2017 to November 2017, Mr. Xue was the director of analytics of Xi'an United Nations Safety Evaluation Center (西安國聯安全評價中心). From December 2017 to July 2018, he was the project manager of Shanghai Xihua Scientific Co., Ltd. (上海熙華檢測技術服務有限公司). Since August 2018, Mr. Xue has been the deputy general manager of Caresun Pharmaceutical. Mr. Xue obtained a bachelor's degree majoring in applied chemistry from Nanjing Agricultural University in June 2009.

Subject to the Shareholders approving the proposed appointment of Mr. Xue as a non-executive Director at the EGM, the Company will enter into a letter of appointment with Mr. Xue for the term of office commencing from the date of which his appointment is approved at the EGM and continue until the expiry of the term of the current session of the Board, and he will be eligible for re-election upon the expiry of his term of office. The proposed director's fee for Mr. Xue shall be RMB250,000 per annum (tax inclusive), which has been recommended by the remuneration committee of the Board and approved by the Directors with reference to, inter alia, his qualifications and experience, duties and responsibilities with the Company, and the prevailing market conditions.

Save as disclosed in this announcement, as of the date of this announcement, Mr. Xue has confirmed that (i) he does not hold any position with the Company or any other member of the Group; (ii) he has not held any directorship in any public company listed on any securities market in Hong Kong or overseas during the past three years; (iii) he does not have any relationship with any Director, member of the senior management, substantial shareholder or controlling shareholder of the Company; (iv) he does not have any interest or short position in any shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "**SFO**"); and (v) there is no other information relating to his proposed appointment that is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**") nor are there any other matters that need to be brought to the attention of the Shareholders.

General

A circular containing, among other things, further information on the proposed appointment of Mr. Xue as a non-executive Director, together with the notice of the EGM, will be published on the websites of the Company and the Stock Exchange in due course.

PROPOSED IMPLEMENTATION OF THE H SHARE FULL CIRCULATION

This announcement is made by the Company pursuant to Rule 13.09(2) of the Listing Rules and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the SFO.

Reference is made to the Guidelines on Application for "Full Circulation" of Domestic Unlisted Shares of H-share Companies (《H股公司境內未上市股份申請「全流通」業務指引》) issued by the China Securities Regulatory Commission (the "**CSRC**") on November 14, 2019 and further amended on August 10, 2023 (the "**Guidelines**") regarding the procedures of application by companies whose H shares are listed on the Stock Exchange for circulation of domestic unlisted shares (as defined under the Guidelines) on the Stock Exchange.

In view of the Guidelines, the Board has considered and approved the proposal for the implementation of the H share full circulation, which is to convert 1,262,882 unlisted shares of the Company (the "**Unlisted Shares**") into H shares (the "**H Shares**") of the Company (the "**H Share Full Circulation**"). Pursuant to the articles of association of the Company, no approval from the Shareholders at general meeting is required for the H Share Full Circulation and the Conversion and Listing (as defined below).

As of the date of this announcement, the Company has not yet submitted any documents for filing an application for the H Share Full Circulation to the CSRC. Subject to obtaining all relevant approvals and/or filing (including the filing notice from the CSRC and the approval from the Stock Exchange) and having complied with all applicable laws, rules and regulations, such Unlisted Shares will be converted into H Shares and the Company will apply to the Stock Exchange for the listing of, and permission to deal in, such H Shares on the Main Board of the Stock Exchange (the "**Conversion and Listing**").

The Company will make further announcement(s) on the progress of the H Share Full Circulation and the Conversion and Listing in accordance with the requirements of the Listing Rules and/or the Inside Information Provisions, as and when appropriate.

The H Share Full Circulation and the Conversion and Listing are subject to other relevant procedures as required by the CSRC, the Stock Exchange and other domestic and overseas regulatory authorities. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
LongBio Pharma (Suzhou) Co., Ltd.
Dr. Liu Heng
Chairman of the Board and Executive Director

Hong Kong, August 21, 2026

As of the date of this announcement, the Board comprises (i) Dr. LIU Heng, Dr. SUN Bill Nai-chau and Mr. XIE Ming as executive Directors; (ii) Mr. LIN Jian, Ms. GU Qin, Dr. XUE Di and Dr. CHEN Kan as non-executive Directors; and (iii) Mr. SIU Paul Yu Hay, Mr. RUAN Tim, Mr. YANG Chun and Mr. ZHOU Guofang as independent non-executive Directors.